Expression and clinical significance of miR‑23a and MTSS1 in diffuse large B‑cell lymphoma

Xu,Mengwei; Xu,Tao

doi:10.3892/ol.2018.8657

Expression and clinical significance of miR‑23a and MTSS1 in diffuse large B‑cell lymphoma

Authors:
- Mengwei Xu
- Tao Xu
View Affiliations

Affiliations: Department of Pathology, Xijing Hospital, Xi'an, Shanxi 710000, P.R. China
Published online on: May 7, 2018 https://doi.org/10.3892/ol.2018.8657
Pages: 371-377

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the expression and clinical significance of micro‑ribonucleic acid‑23a (miR‑23a) and metastasis suppressor 1 (MTSS1) in diffuse large B‑cell lymphoma (DLBCL). A total of 70 cases of tumor tissues of patients with DLBCL and 30 cases of reactive lymphoid hyperplasia tissues were collected. OCI-LY10 cell was transfected with miR-23a antisense oligonucleotide (miR-23a ASO). The expression of miR‑23a and MTSS1 in tumor tissues of patients with DLBCL and reactive lymphoid hyperplasia tissues were detected by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and immunohistochemistry. Spearman's test was used for correlation analysis was also performed for their expression. The relationship of the expressions of miR‑23a and MTSS1 with the pathological parameters of patients with DLBCL was further analyzed. The DLBCL OCI‑LY10 cells were cultured in vitro, and gene silencing downregulated the expression of miR‑23a in OCI‑LY10 cells. The expression of miR‑23a was studied via RT‑qPCR, and the effect of downregulation of miR‑23a on MTSS1 protein expression was determined by western blot analysis. Moreover, the effects of miR‑23a on the proliferation, metastasis and invasion capacities of OCI‑LY10 cells were observed by both methyl thiazolyl tetrazolium (MTT) assay and Transwell chamber assay. The results of RT‑qPCR showed that the mRNA expression of miR‑23a in DLBCL tissues was significantly higher than that of reactive hyperplasia tissues. Immunohistochemical results revealed that the positive expression rate of MTSS1 in DLBCL tissues (30.00%) was significantly lower in comparison to reactive hyperplasia tissues (90.00%). Correlation analysis revealed that the miR‑23a expression had a significant negative correlation with MTSS1 expression (r=‑0.538, p=0.01). The expression of miR‑23a and MTSS1 were correlated with the Ann Arbor staging, extranodal invasion and International Prognostic Index (IPI) scores of patients (p<0.05). However, they had no significant correlation with the sex and age of patients (p>0.05). After the downregulation of miR‑23a expression, the MTSS1 protein expression in OCI‑LY10 cells showed a significant increase. However, the proliferation, metastasis and invasion capacities of OCI‑LY10 cells were obviously decreased. In conclusion, miR‑23a promoted the proliferation, invasion and metastasis of DLBCL OCI‑LY10 cells through the targeted inhibition of MTSS1. The high expression of miR‑23a and the low expression of MTSS1 protein could be used as reference indexes for the prognosis of DLBCL.

View Figures

View References

1	Vaidya R and Witzig TE: Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol. 25:2124–2133. 2014. View Article : Google Scholar : PubMed/NCBI
2	Smith A, Howell D, Patmore R, Jack A and Roman E: Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. Br J Cancer. 105:1684–1692. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 103:275–282. 2004. View Article : Google Scholar : PubMed/NCBI
4	Shankland KR, Armitage JO and Hancock BW: Non-Hodgkin lymphoma. Lancet. 380:848–857. 2012. View Article : Google Scholar : PubMed/NCBI
5	Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, et al: Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma: ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 24:561–576. 2013. View Article : Google Scholar : PubMed/NCBI
6	Essadi I, Ismaili N, Tazi E, Elmajjaoui S, Saidi A, Ichou M and Errihani H: Primary lymphoma of the head and neck: Two case reports and review of the literature. Cases J. 1:4262008. View Article : Google Scholar : PubMed/NCBI
7	PDQ Adult Treatment Editorial Board: Adult Non-Hodgkin Lymphoma Treatment (PDQ): Health Professional VersionPDQ Cancer Information Summaries [Internet]. National Cancer Institute (US); Bethesda: 2002
8	Dogan A, Bagdi E, Munson P and Isaacson PG: CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 24:846–852. 2000. View Article : Google Scholar : PubMed/NCBI
9	Chhabra R, Dubey R and Saini N: Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Mol Cancer. 9:2322010. View Article : Google Scholar : PubMed/NCBI
10	Chhabra R, Adlakha YK, Hariharan M, Scaria V and Saini N: Upregulation of miR-23a-27a-24-2 cluster induces caspase-dependent and -independent apoptosis in human embryonic kidney cells. PLoS One. 4:e58482009. View Article : Google Scholar : PubMed/NCBI
11	Kong KY, Owens KS, Rogers JH, Mullenix J, Velu CS, Grimes HL and Dahl R: MIR-23A microRNA cluster inhibits B-cell development. Exp Hematol. 38(629–640): e12010.
12	Schetter AJ, Nguyen GH, Bowman ED, Mathé EA, Yuen ST, Hawkes JE, Croce CM, Leung SY and Harris CC: Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res. 15:5878–5887. 2009. View Article : Google Scholar : PubMed/NCBI
13	Wang WL, Yang C, Han XL, Wang R, Huang Y, Zi YM and Li JD: MicroRNA-23a expression in paraffin-embedded specimen correlates with overall survival of diffuse large B-cell lymphoma. Med Oncol. 31:9192014. View Article : Google Scholar : PubMed/NCBI
14	Du P, Ye L, Li H, Yang Y and Jiang WG: The tumour suppressive role of metastasis suppressor-1, MTSS1, in human kidney cancer, a possible connection with the SHH pathway. J Exp Ther Oncol. 10:91–99. 2012.PubMed/NCBI
15	Jahid S, Sun J, Edwards RA, Dizon D, Panarelli NC, Milsom JW, Sikandar SS, Gümüs ZH and Lipkin SM: miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov. 2:540–553. 2012. View Article : Google Scholar : PubMed/NCBI
16	Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM: bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003. View Article : Google Scholar : PubMed/NCBI
17	Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, et al: MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 7:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
18	Du T and Zamore PD: microPrimer: The biogenesis and function of microRNA. Development. 132:4645–4652. 2005. View Article : Google Scholar : PubMed/NCBI
19	Bushati N and Cohen SM: microRNA functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
20	Rao SA, Santosh V and Somasundaram K: Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol. 23:1404–1417. 2010. View Article : Google Scholar : PubMed/NCBI
21	Deng D, Wang L, Chen Y, Li B, Xue L, Shao N, Wang Q, Xia X, Yang Y and Zhi F: MicroRNA-124-3p regulates cell proliferation, invasion, apoptosis, and bioenergetics by targetingPIM1 in astrocytoma. Cancer Sci. 107:899–907. 2016. View Article : Google Scholar : PubMed/NCBI
22	Hu X, Chen D, Cui Y, Li Z and Huang J: Targeting microRNA-23a to inhibit glioma cell invasion via HOXD10. Sci Rep. 3:34232013. View Article : Google Scholar : PubMed/NCBI
23	Lee SH, Kerff F, Chereau D, Ferron F, Klug A and Dominguez R: Structural basis for the actin-binding function of missing-in-metastasis. Structure. 15:145–155. 2007. View Article : Google Scholar : PubMed/NCBI
24	Lee YG, Macoska JA, Korenchuk S and Pienta KJ: MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia. 4:291–294. 2002. View Article : Google Scholar : PubMed/NCBI
25	Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z, et al: miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res. 9:824–833. 2011. View Article : Google Scholar : PubMed/NCBI
26	Wang Z, Wei W and Sarkar FH: miR-23a, a critical regulator of ‘migR’ ation and metastasis in colorectal cancer. Cancer Discov. 2:489–491. 2012. View Article : Google Scholar : PubMed/NCBI
27	Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, et al: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
28	Parr C and Jiang WG: Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer. 45:1673–1683. 2009. View Article : Google Scholar : PubMed/NCBI